BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a hold rating to a buy rating in a research note issued to investors on Friday morning.

ATRS has been the topic of several other research reports. HC Wainwright set a $5.00 price target on shares of Antares Pharma and gave the stock a buy rating in a research report on Friday, October 13th. Piper Jaffray Companies set a $3.00 price target on shares of Antares Pharma and gave the stock a buy rating in a research report on Monday, October 23rd. Finally, ValuEngine lowered shares of Antares Pharma from a hold rating to a sell rating in a research report on Monday, October 16th. One research analyst has rated the stock with a sell rating, four have given a buy rating and two have given a strong buy rating to the company. Antares Pharma currently has a consensus rating of Buy and an average price target of $3.84.

Antares Pharma (NASDAQ:ATRS) opened at $2.05 on Friday. Antares Pharma has a 52-week low of $1.58 and a 52-week high of $4.09. The stock has a market cap of $320.63, a P/E ratio of -18.64 and a beta of 0.26. The company has a current ratio of 3.34, a quick ratio of 2.89 and a debt-to-equity ratio of 0.69.

Antares Pharma (NASDAQ:ATRS) last announced its earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.03). Antares Pharma had a negative net margin of 32.06% and a negative return on equity of 43.05%. The firm had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.01 million. The company’s revenue was up 11.9% on a year-over-year basis. sell-side analysts expect that Antares Pharma will post -0.11 earnings per share for the current year.

In related news, Director Leonard S. Jacob sold 230,000 shares of the stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $4.05, for a total transaction of $931,500.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Thomas J. Garrity sold 30,000 shares of the stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $3.50, for a total transaction of $105,000.00. The disclosure for this sale can be found here. Company insiders own 11.60% of the company’s stock.

A number of large investors have recently modified their holdings of ATRS. Capital Advantage Inc. bought a new position in Antares Pharma in the 3rd quarter valued at approximately $110,000. Alliancebernstein L.P. bought a new position in Antares Pharma in the 2nd quarter valued at approximately $119,000. Legal & General Group Plc bought a new position in Antares Pharma in the 2nd quarter valued at approximately $120,000. MML Investors Services LLC lifted its stake in Antares Pharma by 228.2% in the 2nd quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock valued at $139,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Credit Suisse AG bought a new position in Antares Pharma in the 1st quarter valued at approximately $146,000. 34.63% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This article was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://theolympiareport.com/2017/12/25/antares-pharma-atrs-upgraded-at-bidaskclub.html.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with Analyst Ratings Network's FREE daily email newsletter.